MMV and Novartis recently announced an expansion to their current partnership. Novartis will be taking the lead in the development of the antimalarial compound KAF156, which has scientific and financial support from MMV and Bill and Melinda Gates Foundation.
According to Joseph Jimenez, CEO of Novartis: “With a child dying from malaria every two minutes and the threat of drug resistance growing year-on-year, there is a real urgency to step up global efforts to combat this disease. Partnerships and collaborations like this one with MMV are essential for the development of next generation antimalarials and accelerating efforts to eradicate this deadly disease.”
KAF156 is one of the first antimalarial drugs to enter Phase IIb clinical development in more than 20 years, working against two parasites that are responsible for the majority of malaria deaths, Plasmodium falciparum and Plasmodium vivax. KAF156 continues in the footsteps of Novartis’s first fixed-dose Artemisinin-based Combination Therapy, Coartem®, which was launched in 1999.
Dr. David Reddy, CEO of MMV, added: “We are delighted to extend our partnership with Novartis in the development of this exciting candidate antimalarial medicine with the potential to tackle drug resistance and improve patient compliance. As such, this agreement marks an important milestone, as MMV continues its mission to discover, develop and deliver new, effective and affordable antimalarials to the patients who need them most.”
For more information on this, please go to: http://www.mmv.org/newsroom/press-releases/mmv-and-novartis-expand-partnership